M. Campion

912 total citations
20 papers, 708 citations indexed

About

M. Campion is a scholar working on Immunology, Infectious Diseases and Oncology. According to data from OpenAlex, M. Campion has authored 20 papers receiving a total of 708 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Immunology, 4 papers in Infectious Diseases and 4 papers in Oncology. Recurrent topics in M. Campion's work include Antimicrobial Resistance in Staphylococcus (4 papers), Infective Endocarditis Diagnosis and Management (4 papers) and Hematopoietic Stem Cell Transplantation (4 papers). M. Campion is often cited by papers focused on Antimicrobial Resistance in Staphylococcus (4 papers), Infective Endocarditis Diagnosis and Management (4 papers) and Hematopoietic Stem Cell Transplantation (4 papers). M. Campion collaborates with scholars based in United States, Lebanon and United Kingdom. M. Campion's co-authors include Marc B. Garnick, Helen W. Boucher, Susan J. Rehm, Gloria Vigliani, Donald P. Levine, Jehan Alam, Amy M. Salazar, Diane L. Cookfair, Bianca Weinstock‐Guttman and R. A. Rudick and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

M. Campion

20 papers receiving 670 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. Campion United States	12	224	171	166	123	118	20	708
Maria Casteels‐Van Daele Belgium	18	105 0.5×	56 0.3×	85 0.5×	94 0.8×	58 0.5×	53	934
Masataka Ishimura Japan	16	70 0.3×	100 0.6×	131 0.8×	76 0.6×	113 1.0×	97	744
Alejandro Darnell Spain	17	85 0.4×	63 0.4×	27 0.2×	76 0.6×	61 0.5×	26	1.3k
Mickaël Schaeffer France	17	100 0.4×	29 0.2×	141 0.8×	121 1.0×	260 2.2×	42	881
Oren Pasvolsky Israel	14	84 0.4×	68 0.4×	137 0.8×	42 0.3×	49 0.4×	64	609
Edythe A. Albano United States	13	77 0.3×	128 0.7×	202 1.2×	19 0.2×	128 1.1×	24	714
A.M.Z. Chang Hong Kong	17	55 0.2×	94 0.5×	96 0.6×	70 0.6×	163 1.4×	35	923
Ömer Uluoğlu Türkiye	16	189 0.8×	71 0.4×	216 1.3×	116 0.9×	75 0.6×	71	685
Stefania Gaspari Italy	15	42 0.2×	53 0.3×	96 0.6×	44 0.4×	50 0.4×	46	659

Countries citing papers authored by M. Campion

Since Specialization

Citations

This map shows the geographic impact of M. Campion's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Campion with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Campion more than expected).

Fields of papers citing papers by M. Campion

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Campion. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Campion. The network helps show where M. Campion may publish in the future.

Co-authorship network of co-authors of M. Campion

This figure shows the co-authorship network connecting the top 25 collaborators of M. Campion. A scholar is included among the top collaborators of M. Campion based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Campion. M. Campion is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Campion, M., Adam Labadorf, Thor D. Stein, et al.. (2025). Perinatal Choline Supplementation Promotes Resilience Against Progression of Alzheimer's Disease‐Like Brain Transcriptomic Signatures in App ^NL‐G‐F Mice. Aging Cell. 24(11). e70148–e70148. 1 indexed citations

2.

Campion, M., et al.. (2024). Perinatal choline supplementation prevents learning and memory deficits and reduces brain amyloid Aβ42 deposition in AppNL-G-F Alzheimer’s disease model mice. PLoS ONE. 19(2). e0297289–e0297289. 6 indexed citations

3.

Borowitz, Drucy, et al.. (2010). Reproducibility of coefficient of fat absorption (CFA) in cystic fibrosis patients with pancreatic insufficiency. Journal of Cystic Fibrosis. 9. S77–S77. 3 indexed citations

4.

Stevens, Christopher, et al.. (2010). Evaluation of growth in peri-pubertal cystic fibrosis (CF) subjects with exocrine pancreatic insufficiency (EPI) treated with the novel non-porcine pancreatic enzyme replacement therapy liprotamase. Journal of Cystic Fibrosis. 9. S87–S87. 1 indexed citations

5.

Rehm, Susan J., et al.. (2009). Community-based outpatient parenteral antimicrobial therapy (CoPAT) for Staphylococcus aureus bacteraemia with or without infective endocarditis: analysis of the randomized trial comparing daptomycin with standard therapy. Journal of Antimicrobial Chemotherapy. 63(5). 1034–1042. 47 indexed citations

6.

Kanafani, Zeina A., Wissam M. Kourany, Vance G. Fowler, et al.. (2009). Clinical characteristics and outcomes of diabetic patients with Staphylococcus aureus bacteremia and endocarditis. European Journal of Clinical Microbiology & Infectious Diseases. 28(12). 1477–1482. 33 indexed citations

7.

Rehm, Susan J., Helen W. Boucher, Donald P. Levine, et al.. (2008). Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates. Journal of Antimicrobial Chemotherapy. 62(6). 1413–1421. 87 indexed citations

8.

Lalani, Tahaniyat, Helen W. Boucher, Sara E. Cosgrove, et al.. (2007). Outcomes with daptomycin versus standard therapy for osteoarticular infections associated with Staphylococcus aureus bacteraemia. Journal of Antimicrobial Chemotherapy. 61(1). 177–182. 50 indexed citations

9.

Garnick, Marc B., et al.. (2004). The effect of hormonal therapy for prostate cancer on the electrocardiographic QT interval: phase 3 results following treatment with leuprolide and goserelin, alone or with bicalutamide, and the GnRH antagonist abarelix. Journal of Clinical Oncology. 22(14_suppl). 4578–4578. 16 indexed citations

10.

Garnick, Marc B., et al.. (2004). The effect of hormonal therapy for prostate cancer on the electrocardiographic QT interval: phase 3 results following treatment with leuprolide and goserelin, alone or with bicalutamide, and the GnRH antagonist abarelix. Journal of Clinical Oncology. 22(14_suppl). 4578–4578. 34 indexed citations

11.

Pratt, C B, et al.. (2004). 217 Increase in the electrocardiographic QTC interval in men with prostate cancer undergoing androgen deprivation therapy: Results of three randomized controlled clinical studies. European Urology Supplements. 3(2). 57–57. 7 indexed citations

12.

Garnick, Marc B. & M. Campion. (2000). Abarelix Depot, a GnRH antagonist, v LHRH superagonists in prostate cancer: differential effects on follicle-stimulating hormone. Abarelix Depot study group.. PubMed. 4(3). 275–7. 45 indexed citations

13.

Martha, P M, et al.. (1999). O-8 Abarelix-Depot, a potent pure GnRH antagonist, rapidly induced sustained suppression of the pituitary -gonadal axis in women with endometriosis. Fertility and Sterility. 71(4). 9S–9S. 1 indexed citations

14.

Rudick, R. A., Nancy A. Simonian, Jehan Alam, et al.. (1998). Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Neurology. 50(5). 1266–1272. 262 indexed citations

15.

Rinehart, J. J., Kim Margolin, Pierre L. Triozzi, et al.. (1995). Phase I trial of recombinant interleukin 3 before and after carboplatin/etoposide chemotherapy in patients with solid tumors: a southwest oncology group study.. PubMed. 1(10). 1139–44. 3 indexed citations

16.

Grinblatt, David L., et al.. (1995). Phase I multicenter trial of interleukin 6 therapy after autologous bone marrow transplantation in advanced breast cancer.. PubMed. 15(6). 935–42. 25 indexed citations

17.

Fay, JW, Hillard Lazarus, R H Herzig, et al.. (1994). Sequential administration of recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a phase I/II multicenter study. Blood. 84(7). 2151–2157. 1 indexed citations

18.

Fay, JW, Hillard Lazarus, R H Herzig, et al.. (1994). Sequential administration of recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a phase I/II multicenter study. Blood. 84(7). 2151–2157. 21 indexed citations

19.

Nemunaitis, John, FR Appelbaum, Jack W. Singer, et al.. (1993). Phase I trial with recombinant human interleukin-3 in patients with lymphoma undergoing autologous bone marrow transplantation. Blood. 82(11). 3273–3278. 39 indexed citations

20.

Itri, Loretta M., Morris Sherman, Alicia V. Palleroni, et al.. (1989). Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon-alpha 2a.. PubMed. 9 Suppl 1. S9–15. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact